運輸方式： 凍存運輸
ATCC Number： CRL-5911?
相關(guān)**： 腺癌
數(shù)量： 大量
細(xì)胞形態(tài)： 上皮樣
器官來源： 肺
是否是腫瘤細(xì)胞： 0
物種來源： 人
年限： stage 4
Designations: NCI-H2009 [H2009]
Depositors: AF Gazdar, JD Minna
Biosafety Level: 1
Shipped: frozen
NCI-H2009細(xì)胞Medium & Serum: See Propagation
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: lung
Tumor Stage: stage 4
Disease: adenocarcinoma
Derived from metastatic site: lymph node
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. NCI-H2009細(xì)胞They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR): Amelogenin: X
CSF1PO: 10,12
D13S317: 12
D16S539: 12
D5S818: 13
D7S820: 9,11
THO1: 9.3
TPOX: 8
vWA: 14
Age: 68 years
Gender: female
Ethnicity: Caucasian
NCI-H2009細(xì)胞Comments: The line was established in August 1988.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
30 pack years.
A lymphoblastoid line from the same patient is available as ATCC CRL-5961.
Propagation: ATCC complete growth medium: HITES medium supplemented with 5% fetal bovine serum
The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No.30-2006. To make the complete growth medium,add the following components to the base medium
0.005 mg/ml Insulin
0.01 mg/ml Transferrin
30nM Sodium selenite (final conc.)
10 nM Hydrocortisone (final conc.)
10 nM beta-estradiol (final conc.)
extra 2mM L-glutamine (for final conc. of 4.5 mM)
5% fetal bovine serum (final conc.)
Preservation: 85% Complete Growth Medium + 10% FBS + 5% DMSO.
Related Products: Recommended mediumNCI-H2009細(xì)胞 (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
normal (or near-normal) cell line established from the same patient:ATCC CRL-5961
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
